Haematology

News

Leschly steps down as 2seventy wields the axe

2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also

News

AI specialist Intelligent Omics bags J&J deal

UK artificial intelligence (AI) specialist Intelligent Omics has entered into a research collaboration with Johnson & Johnson, within weeks of joining the big pharma's

News

FDA places Gilead's CD47 drug on another clinical hold

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloi

News

Humanigen facing bankruptcy as reverse merger fails

Three years ago, Humanigen was riding high with a COVID-19 therapy in late-stage testing and shares worth upwards of $20 apiece.

News

Gilead drops magrolimab for myelodysplastic syndromes

Gilead Sciences has said it will stop the development of its cancer antibody magrolimab in blood cancer myelodysplastic syndromes (MDS) after disappointing results in a ph

News

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a

Leschly steps down as 2seventy wields the axe

AI specialist Intelligent Omics bags J&J deal

FDA places Gilead's CD47 drug on another clinical hold

Humanigen facing bankruptcy as reverse merger fails

Gilead drops magrolimab for myelodysplastic syndromes

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Haematology

Editor's Picks